


**Product Name** : Decernotinib  
**Cat. No.** : PC-43049  
**CAS No.** : 944842-54-0  
**Molecular Formula** : C<sub>18</sub>H<sub>19</sub>F<sub>3</sub>N<sub>6</sub>O  
**Molecular Weight** : 392.3783  
**Target** : JAK  
**Solubility** : 10 mM in DMSO



## Biological Activity

Decernotinib (VX-509, VRT-831509) is a potent, selective, orally available JAK3 inhibitor with  $K_i$  of 2.5 nM and cellular IC<sub>50</sub> of 50-170 nM, demonstrates limited inhibition of JAK1/JAK2/TYK2 in cell-based assays (25-100 fold); also inhibits JAK1, JAK2 and TYK2 ( $K_i$ =11, 13 and 11 nM) in biochemical assay and shows >400-fold selectivity over a broad kinases; inhibits IL-2-induced STAT-5 phosphorylation in IL-2-dependent T-cell line with IC<sub>50</sub> of 99 nM, potently suppresses T-cell proliferation with IC<sub>50</sub> of 170 nM; modulates proinflammatory response in models of immune-mediated diseases, such as collagen-induced arthritis and delayed-type hypersensitivity.

Rheumatoid Arthritis  
Phase 2 Discontinued

## References

- Farmer LJ, et al. J Med Chem. 2015 Sep 24;58(18):7195-216.  
Mahajan S, et al. J Pharmacol Exp Ther. 2015 May;353(2):405-14.  
Genovese MC, et al. Arthritis Rheumatol. 2016 Jan;68(1):46-55.  
Genovese MC, et al. Ann Rheum Dis. 2016 Nov;75(11):1979-1983.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com